Table 3: Overall survival and values of Atezolizumab and Pembrolizomab.

Drug and setting OS gains in days/Grade (OS/gr) & HR $C/LYG RV
Atezo vs. Docetaxel (Doc), irrespective of PD-L1, vs. Docetaxel (phase II, Poplar) [8] 87/C HR 0.73
P = 0.040
$618,244 0.16
Atezo, squamous and non-squamous, regardless of PD-L1 vs. Doc (OAK) [9] 128/B HR 0.74
P = 0.0004
$420,213 0.24
Atezo, low or undetectable PD-L1 vs. Doc, Phase III OAK [10] 111/B HR 0.75 $484,570 0.21
Atezo, PD-L1 > 1.0% or tumor-infiltrating immune cells vs. Doc [10] 162/A HR 0.74
P = 0.0102
$332,020 0.30
Pembro PD-L1 > 1.0% positive vs. Doc Keynote-010 [7] Subset analysis 57/C
HR 0.71
P = 0.0008
$659,059 0.15
Pembro 10 mg/Kg, PD-L1 1.0% positive, Keynote-010 126/A
HR 0.61
$1,490,729 0.07
Pembro 2.0 mg/Kg, > 50% positive Keynote-010 201/A
HR 0.54
$186,897 0.53